The study maps the core organization of the trans-spliceosome, detailing RNA positioning during the reaction and highlighting parasite-specific proteins absent in humans, illustrating evolutionary remodeling of this ancient machinery.

In Nature Communications, the work titled Structural basis of step II spliced leader RNA trans-splicing in trypanosomatid parasites presents two-stage cryo-EM snapshots and was published on September 23, 2026.

The publication provides the DOI 10.1038/s41467-026-77480-6 and situates the findings within the broader context of parasite RNA processing research.

Crucially, the findings offer a concrete basis for designing molecules that specifically disrupt the parasite trans-spliceosome while sparing human cells, signaling potential new treatments for tropical diseases.

The research shows that nearly all parasite mRNAs receive the same SL RNA at their 5' end, a mechanism absent in humans and thereby presenting a drug-targetable vulnerability.

Cryo-EM captures two successive states of the trans-spliceosome: SL RNA attachment to mRNA and the immediate post-reaction state, providing high-resolution structural insight.

The work advances understanding of RNA processing in eukaryotes and points toward new therapeutic strategies against trypanosomatid diseases such as leishmaniasis, sleeping sickness, and Chagas’ disease.

Researchers from Liège and Rockefeller University mapped near-atomic structures and functions of the trans-spliceosome, a giant molecular machine essential for RNA processing in trypanosomatid parasites.

Despite similarities to human splicing, the trypanosomatid trans-spliceosome exhibits distinctive adaptations that are critical for parasite survival and represent selective targets.

The study provides evolutionary insight into how ancient molecular machines remodel for parasite-specific roles and offers a practical basis for designing inhibitors with reduced risk to human cells.